Table 2.
Stage 2/replication study characteristics
| Genome-wide association follow-up | Cases (n) | Control subjects (n) | Population | T2D phenotype | Confirmed T2D loci reported |
|---|---|---|---|---|---|
| Sladek et al. [5] | 2617 | 2894 | France | BMI < 35 kg/m2 | TCF7L2, SLC30A8, HHEX/IDE |
| Zeggini et al.*[2] | 3757 | 5346 | UK | Partial enrichment for AAO < 45 years | TCF7L2, CDKAL1, CDKN2A/B, HHEX/IDE, SLC30A8, IGF2BP2, FTO, PPARG, KCNJ11* |
| Scott et al.*[1] | 1215 | 1258 | Finland | No specific enrichment | TCF7L2, CDKAL1, CDKN2A/B, HHEX/IDE, SLC30A8, IGF2BP2, FTO, PPARG, KCNJ11* |
| DGI*[4] | 5065 | 5785 | European ancestry† | No specific enrichment | TCF7L2, CDKAL1, CDKN2A/B, HHEX/IDE, SLC30A8, IGF2BP2, FTO, PPARG, KCNJ11* |
| Steinthorsdottir et al. [6] | 3826 | 12562 | European ancestry‡ | No specific enrichment | TCF7L2, CDKAL1, SLC30A8, HHEX/IDE |
| 1457 | 986 | Hong Kong | Partial enrichment for AAO < 40 years | ||
| 865 | 1106 | West Africa | Family history of T2D |
*
The Zeggini et al. [2], Scott et al. [4] and DGI [3] replication studies included meta-analysis of primary scan and stage 2 datasets from each of the three studies.
†
From Sweden, Poland and the USA.
‡
From Denmark, Philadelphia and the Netherlands.
AAO, age at onset; BMI, body mass index; DGI, Diabetes Genetics Initiative; T2D, Type 2 diabetes.